Curbing hepatitis C virus spread in Egypt

The Lancet Global Health

Volumn 2, Issue 9, 2014, Pages e495-e496

  Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; OPIATE; RIBAVIRIN;

BLOOD TRANSFUSION; BLOODBORNE BACTERIUM; DRUG ADMINISTRATION; DRUG COST; DRUG SUBSTITUTION; EGYPT; HEALTH CARE FACILITY; HEALTH CARE PERSONNEL; HEALTH PROGRAM; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MATHEMATICAL MODEL; MEDICAL PROCEDURES; NOTE; PREVALENCE; SCHISTOSOMIASIS; SYRINGE; UNSAFE INJECTION; VIRUS TRANSMISSION; CROSS INFECTION; HEPACIVIRUS; HEPATITIS C; INFECTION CONTROL; PROCEDURES; THEORETICAL MODEL;

CROSS INFECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; INFECTION CONTROL; MODELS, THEORETICAL;

EID: 84908453951     PISSN: None     EISSN: 2214109X     Source Type: Journal    
DOI: 10.1016/S2214-109X(14)70292-X     Document Type: Note

References (11)

1. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-62.
2. Hutin YJ, Hauri AM, Armstrong GL. Use of injections in healthcare settings worldwide, 2000: literature review and regional estimates. BMJ 2003; 327: 1075.
3. Kane A, Lloyd J, Zaffran M, Simonsen L, Kane M. Transmission of hepatitis B, hepatitis C and human immunodefi ciency viruses through unsafe injections in the developing world: model-based regional estimates. Bull World Health Organ 1999; 77: 801-07.
4. Breban R, Doss W, Esmat G, et al. Towards realistic estimates of HCV incidence in Egypt. J Viral Hepat 2013; 20: 294-96.
5. Frank C, Mohamed MK, Strickland GT, et al. The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet 2000; 355: 887-91.
6. Breban R, Arafa N, Leroy S, et al. Eff ect of preventive and curative interventions on hepatitis C virus transmission in Egypt (ANRS 1211): a modelling study. Lancet Glob Health 2014; 2: e541-49.
7. Hanenberg RS, Rojanapithayakorn W, Kunasol P, Sokal DC. Impact of Thailand's HIV-control programme as indicated by the decline of sexually transmitted diseases. Lancet 1994; 344: 243-45.
8. Tanser FF, Bärnighausen TT, Grapsa EE, Zaidi JJ, Newell M-LM. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science 2013; 339: 966-71.
9. Martin NK, Vickerman P, Grebely J, et al. HCV treatment for prevention among people who inject drugs: modeling treatment scale-up in the age of direct-acting antivirals. Hepatology 2013; 58: 1598-609.
10. Wandeler G, Gasponer T, Bregenzer A, et al, for the Swiss HIV Cohort Study. Hepatitis C virus infections in the Swiss HIV Cohort Study: a rapidly evolving epidemic. Clin Infect Dis 2012; 55: 1408-16.
11. Allwright S, Bradley F, Long J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000; 321: 78-82.